Faculty Research at Morehead State University


William Green

Document Type


Publication Date



Depo-Provera has been a scientific and political battleground for over twenty years. At stake have been the reproductive health of women, the marketing of a long-acting contraceptive by a multinational corporation, and international family planning and population control. Seventy nations have approved its use as a female contraceptive, but the U.S. Food and Drug Administration (FDA) has not, because the drug is a suspected carcinogen. FDA's decision means marketing of Depo-Provera as a contraceptive is forbidden in the United States and in U.S. foreign aid programs. FDA's decision also means the drug is less likely to be used in Third World family planning programs.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.